The Journal of Pediatrics
Volume 150, Issue 6 , Pages 572-574 , June 2007

Focus on the Heart and Aorta in Turner Syndrome

  • Angela E. Lin, MD

      Affiliations

    • Genetics Unit, MassGeneral Hospital for Children, Boston, Massachusetts
    • ,
  • Michael Silberbach, MD

      Affiliations

    • Division of Pediatric Cardiology, Doernbecher Children’s Hospital, Oregon Health & Science University, Portland, Oregon
    • Corresponding Author InformationReprint requests: Michael Silberbach, MD, Department of Pediatrics, CDRC-P, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239.

References 

  1. Matura LA, Sachdev V, Bakalov VK, Rosing DR, Bondy CA. Growth hormone treatment and left ventricular dimensions in Turner syndrome. J Pediatr. 2007;150:587–591
  2. Sas TC, Cromme-Dijkhuis AH, de Muinck Keizer-Schrama SM, Stijnen T, van Teunenbroek A, Drop SL. The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner’s syndrome. J Pediatr. 1999;135:470–476
  3. Bondy CA, Van PL, Bakalov VK, Ho VB. Growth hormone treatment and aortic dimensions in Turner syndrome. J Clin Endocrinol Metab. 2006;91:1785–1788
  4. Lin AE, Lippe B, Rosenfeld RG. Further delineation of aortic dilation, dissection, and rupture in patients with Turner syndrome. Pediatrics. 1998;102:e12
  5. Sybert VP. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. 1998;101:e11
  6. Gravholt CH, Landin-Wilhelmsen K, Stochholm K, Hjerrild BE, Ledet T, Djurhuus CB, et al. Clinical and epidemiological description of aortic dissection in Turner’s syndrome. Cardiol Young. 2006;16:430–436
  7. Ostberg JE, Donald AE, Halcox JP, Storry C, McCarthy C, Conway GS. Vasculopathy in Turner syndrome: arterial dilatation and intimal thickening without endothelial dysfunction. J Clin Endocrinol Metab. 2005;90:5161–5166
  8. Pereira L, Andrikopoulos K, Tian J, Lee SY, Keene DR, Ono R, et al. Targeting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet. 1997;17:218–222
  9. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355:788–798
  10. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117–121
  11. Carlson M, Silberbach M. Dissection of the aorta in Turner syndrome: Two new cases and review of 85 cases in the literature. (Submitted to Pediatrics).
  12. Meszaros I, Morocz J, Szlavi J, Schmidt J, Tornoci L, Nagy L, et al. Epidemiology and clinicopathology of aortic dissection. Chest. 2000;117:1271–1278
  13. Silberbach M. Making treatment decisions for those with congenital heart disease in Turner syndrome: the need for evidence-based medicine. International Congress Series. 2006;1298:131–136(Eds. Bondy CA, Gravholt C, Elsevier)
  14. Bondy CA. Care of girls and women with turner syndrome: a guideline of the turner syndrome study group. J Clin Endocrinol Metab. 2007;92:10–25

PII: S0022-3476(07)00258-2

doi: 10.1016/j.jpeds.2007.03.038

The Journal of Pediatrics
Volume 150, Issue 6 , Pages 572-574 , June 2007

Article Tools

* Image Usage & Resolution